Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

The importance of NF-kB pathway in myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
This video is restricted to members who are registered with ecancer as a healthcare professional
Please login or register for free to confirm your details.
Published: 03.12.18
Views: 948

Dr Nizar Bahlis - University of Calgary, Calgary, Canada

Dr Nizar Bahlis speaks to ecancer at ASH 2018 about the results of the TOURMALINE-MM1 study and the use of proteasome inhibitors.

He explains that the study compares lenalidomide‑dexamethasone with a combination of lenalidomide‑dexamethasone and ixazomib in relapsed/refractory multiple myeloma patients with the combination arm superior in showing improving progression free survival.

Dr Bahlis acknowledges the importance of the NF-κB pathway and that patients with an activated non-canonical NF-κB pathway saw the best benefit from the ixazomib and lenalidomide‑dexamethasone combination.

He also discusses the use proteasome inhibitors (PIs) as a treatment for multiple myeloma patients and the benefit of PI maintenance.

This programme has been supported by an unrestricted educational grant from Takeda.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation